– USA, CA – Edwards Lifesciences Corporation (NYSE: EW) today announced the appointment of Bernard Zovighian as CEO effective on May 11, 2023, to succeed Michael Mussallem who will retire as CEO but will step to Non-Executive Chairman of the Board of Directors.
Bernard Zovighian is currently corporate VP and GM for Edwards’ Transcatheter Mitral and Tricuspid Therapies business and will serve as president of Edwards Lifesciences effective Jan. 1 until he becomes CEO in May, working closely with Mussallem, the Board, and the Executive Leadership Team on a smooth transition.
“It has been a special honor and privilege to lead our team at Edwards Lifesciences for more than 20 years in their immense contributions to helping and advancing care for millions of patients around the world. I am particularly proud of the ‘patients-first’ culture embodied by our employees and the commitment to innovation and excellence that our global teams demonstrate. Our success to date is a testament to our talented executive leadership and passionate global team, and we are well positioned for an even brighter future,” said Micheal Mussallem.
About Bernard Zovighian
Bernard Zovighian joined Edwards in 2015 as VP and GM of Surgical Structural Heart, which included responsibility for the company’s global valve network. He became corporate VP of the surgical business and a member of the Edwards Executive Leadership Team in 2016. He then assumed the role of corporate VP and GM for TMTT in 2018, establishing a global organization focused on transforming care for patients with mitral and tricuspid disease. During his career, Zovighian has launched breakthrough therapies for patients and developed experience across multiple disciplines and general management, including nearly 20 years at Johnson & Johnson in roles such as regional leadership outside of the United States and worldwide president of one of the company’s divisions.
“I am excited to have the opportunity to partner with our people around the world to build upon Edwards’ patient-focused culture and innovation strategy. Edwards has contributed over the last six decades to the advancement of treatments for structural heart disease and critical care patients, and our robust pipeline of technologies will enable us to help even more patients in the future. I look forward to working closely with the Board, Mike and Edwards’ Executive Leadership Team on a smooth transition and further advancing the great work of our global teams,” said Bernard Zovighian.
About Edwards Lifesciences
Edwards Lifesciences is the global leader in patient-focused innovations for structural heart disease and critical care monitoring. We are driven by a passion for patients and dedicated to improving and enhancing lives through partnerships with clinicians and stakeholders across the global healthcare landscape.
For more information: https://www.edwards.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
